Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial (Q34593876)

3 August 2017

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial (English)

1 reference

3 August 2017

1 reference

2

Sara A Quandt

1 reference

3 August 2017

7

Dennis Black

1 reference

3 August 2017

Silvina Levis

1

1 reference

3 August 2017

Desmond Thompson

3

1 reference

3 August 2017

Jean Scott

4

1 reference

3 August 2017

Diane L Schneider

5

1 reference

3 August 2017

Philip D Ross

6

1 reference

3 August 2017

Shailaja Suryawanshi

8

1 reference

3 August 2017

Marc Hochberg

9

1 reference

3 August 2017

John Yates

10

1 reference

3 August 2017

FIT Research Group

11

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Journal of the American Geriatrics Society

3 August 2017

1 reference

3 August 2017

50

1 reference

3 August 2017

3

1 reference

3 August 2017

409-415

1 reference

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

The crippling consequences of fractures and their impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

The clinical impact of vertebral fractures: quality of life in women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Vertebral fracture assessment using a semiquantitative technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Design of the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

Cox's Regression Model for Counting Processes: A Large Sample Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

The second hip fracture an epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1532-5415.2002.50102.X

10.1046/J.1532-5415.2002.50102.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference